Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

Provided are methods relating to compositions that include a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

Pharmaceutical formulations including an inclusion complex of an API with a cyclic oligomer, and methods of forming such pharmaceutical formulations are described.

Particles with a spatial and/or temporal release profile for delivery of different agents at different times to the same cells of a subject have been developed. The particles include a core polymeric particle containing a polymer and a first agent, a tethering moiety, covalent linker or covalent linkage attached to the core particle, and a tethered particle attached to the particle via the tethering moiety, covalent linker or covalent linkage and containing a second agent, where the agents are released at different times within or to the same cells. The first and second agents may be a therapeutic or prophylactic agent, such as an antigen, an immunomodulator, an anti-neoplastic agent, a hormone, an inhibitor, etc. The particles may form compositions for treating diseases with a spatial and/or temporal treatment regimen.

A method of promoting increased cellular hydration in a multicellular organism that is capable of intracellular water permeation includes the step of causing the multicellular organism to ingest an aqueous solution that contains an amount of a carbohydrate clathrate component. There is also a step of enhancing the intracellular permeation. The multicellular organism contains aquaporins, and the causing step involves interaction of the composition with the aquaporins. The cellular hydration promoted and caused by the method is corroborated by a test that uses human-aquaporin-expressed frog oocytes. The test uses single cell Xenopus laevis frog oocytes having expressed human aquaporin AGP1 water channels. There is also a beverage composition that increases lifespan in the multicellular organism, and a beverage composition that promotes cellular hydration when ingested by a multicellular organism.

Dry powder formulations for pulmonary and/or intranasal drug delivery, delivery systems, and methods of making and using thereof have been developed. The dry powder formulation contains particles containing a retinoid and/or a retinoid derivative, such as tamibarotene; and a β-cyclodextrin and/or a β-cyclodextrin derivative. The dry powder formulation allows for improved drug adsorption and bioavailability in vivo. The particles of the dry powder formulation have favorable aerodynamic properties for deposition and retention in the lower and/or upper respiratory tract(s). The dry powder formulation can be prepared using spray-drying or spray-freeze-drying. Inhalation, intratracheal administration, and/or intranasal administration of the dry powder formulation can deliver to a subject an effective amount of the retinoid and/or retinoid derivative to prevent, treat, or ameliorate symptom(s) associated with a respiratory viral infection in the subject.

The present disclosure relates to pharmaceutical formulations including abiraterone and a cyclic oligomer, as well as tablets including such pharmaceutical formulations, methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations or tablets.

Particles using a polymer having a particle size suitable for a drug delivery system (DDS) or the like are provided. A drug and an anti-cancer agent using the particles are provided. Each of the particles comprises a polymer having a structure unit derived from a saccharide compound having a hydroxyl group and having an inclusion property and a structure unit derived from a monomer having a functional group to be reacted with a hydroxyl group, and has the average hydrodynamic radius (R.sub.hav) of 5 to 100 nm. A method for producing the particles comprises a step of mixing a mixed composition comprising a saccharide compound, a monomer, a surfactant, and an alkaline aqueous solution having a pH of 12 or more. A drug compress a hydrophobic physiological active agent, such as α-mangostin contained in the particle, and an anti-cancer agent comprising the drug.

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsus-pension including an active agent complex having a diameter of less than about 100 .Math.m.